Bloodstream infections (BSI) can turn deadly fast, particularly for patients with weakened immune systems. A new study from Houston Methodist Research Institute finds that artificial intelligence can ...
Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results